UPDATE: Galmed Pharma (GLMD) Reports Q2 Loss of $0.17

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. COIN
4. PINS
5. RDDT
6. FSLR
7. SYK
8. DASH
9. SBUX
10. SNDK

Go back to UPDATE: Galmed Pharma (GLMD) Reports Q2 Loss of $0.17

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results

August 2, 2018 7:00 AM EDT

TEL AVIV, Israel, Aug. 2, 2018  /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today provides business update and reports financial results for the three and six months ended June 30, 2018. The Company will host a conference call and webcast at 08:30 ET... More